CIK 0001425205 · Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753254381
- Phone
- 6502607120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Shares withheld for taxes | −4,473 | $3.96 | $18K | 136,274 |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −8,790 | 26,369 | ||
| 2026-06-01 | BILINSKY IGOR Chief Operating Officer | Option exercise | +8,790 | 134,556 | ||
| 2026-06-01 | BILINSKY IGOR Chief Operating Officer | Shares withheld for taxes | −4,473 | $3.96 | $18K | 130,083 |
| 2026-06-01 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −8,790 | 26,369 | ||
| 2026-05-11 | Kirby Daniel Gordon Chief Commercial Officer | Option exercise | +10,000 | 149,381 | ||
| 2026-05-11 | Kirby Daniel Gordon Chief Commercial Officer | Shares withheld for taxes | −2,435 | $3.70 | $9K | 146,946 |
| 2026-05-11 | Kirby Daniel Gordon Chief Commercial Officer | Option exercise · Restricted Stock Units | −10,000 | 70,004 | ||
| 2026-03-09 | Roche Corleen M. Chief Financial Officer | Grant or award · Restricted Stock Units | +132,200 | 132,200 | ||
| 2026-03-09 | Vogt Frederick G Interim CEO & General Counsel | Grant or award · Restricted Stock Units | +235,000 | 235,000 | ||
| 2026-03-09 | Puri Raj K. Chief Regulatory Officer | Grant or award · Restricted Stock Units | +117,500 | 117,500 | ||
| 2026-03-09 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +58,750 | 58,750 | ||
| 2026-03-09 | Kirby Daniel Gordon Chief Commercial Officer | Grant or award · Restricted Stock Units | +132,200 | 132,200 | ||
| 2026-03-09 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +117,500 | 117,500 | ||
| 2026-03-05 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +62,493 | 556,293 | ||
| 2026-03-05 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −26,755 | $4.58 | $123K | 529,538 |
| 2026-03-05 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −62,493 | 125,007 | ||
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise | +31,246 | 148,477 | ||
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Shares withheld for taxes | −16,520 | $4.58 | $76K | 131,957 |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −31,246 | 62,504 |
Page 4 of 14 · 280 trades